Bio-Rad's Clean Lending Book Ahead of Q3 Results

Bio-Rad Laboratories reports Q3 results on October 29 with essentially no short-selling pressure in evidence, a contrast to several life science peers where borrow demand has been more meaningful.

Among the closest correlated names in the sector, Agilent Technologies and Repligen have carried measurably higher short interest through 2026. Bio-Rad's own lending market tells a different story: utilization has been at zero across every reading taken this year, meaning no shares in the lending pool are currently borrowed. FINRA's most recent fortnightly settlement data, from September 30, confirms just one thousand shares short with a single day's volume needed to cover. That is not a positioning signal in either direction; it simply means the stock's price action heading into results is driven entirely by buyers and sellers of the underlying shares, with no short-covering dynamic in play.

The more substantive tension into the print is between the stock's momentum and what analysts think it is worth. Bio-Rad has gained roughly 26% year to date and 4% over the past week alone, closing at $379.50 on October 27. A recent ORTEX stock note flagged a negative analyst price-target differential of around 15%, meaning the consensus target sits well below where the stock is trading. The EPS surprise factor score ranks in the 98th percentile, reflecting a strong track record of beating estimates, but the 30-day forward EPS momentum score has slipped to the 28th percentile, suggesting recent earnings revisions have not kept pace with the share price move. EV/EBITDA has expanded materially over the past 30 days as the price has risen, adding to valuation pressure bears would cite.

The ownership register adds one notable detail. Norman Schwartz, the controlling family shareholder, trimmed his position by nearly 476,000 shares in the most recently reported period, reducing his stake to around 4.6% of shares. That is a large reduction relative to his prior holding, though family control of the company's voting structure means the governance picture remains unchanged. Blue Raven Partners holds 15.2% of shares and First Eagle 9.7%, making the register heavily concentrated at the top.

The print will test whether Bio-Rad's beat-rate on earnings can justify a multiple that has expanded sharply into a period of softer near-term revenue guidance and a market watching the company's Sartorius stake for any further moves.